109 related articles for article (PubMed ID: 9495518)
1. Differential effects of aminosubstituted analogs of hydroxy bisphosphonates on the growth of Dictyostelium discoideum.
Brown RJ; van Beek E; Watts DJ; Löwik CW; Papapoulos SE
J Bone Miner Res; 1998 Feb; 13(2):253-8. PubMed ID: 9495518
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory effects of bisphosphonates on growth of amoebae of the cellular slime mold Dictyostelium discoideum.
Rogers MJ; Watts DJ; Russell RG; Ji X; Xiong X; Blackburn GM; Bayless AV; Ebetino FH
J Bone Miner Res; 1994 Jul; 9(7):1029-39. PubMed ID: 7942149
[TBL] [Abstract][Full Text] [Related]
3. Dissociation of binding and antiresorptive properties of hydroxybisphosphonates by substitution of the hydroxyl with an amino group.
Van Beek E; Löwik C; Que I; Papapoulos S
J Bone Miner Res; 1996 Oct; 11(10):1492-7. PubMed ID: 8889849
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationships of new heterocycle-containing bisphosphonates as inhibitors of bone resorption and as inhibitors of growth of Dictyostelium discoideum amoebae.
Rogers MJ; Xiong X; Brown RJ; Watts DJ; Russell RG; Bayless AV; Ebetino FH
Mol Pharmacol; 1995 Feb; 47(2):398-402. PubMed ID: 7870050
[TBL] [Abstract][Full Text] [Related]
5. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
Dunford JE; Thompson K; Coxon FP; Luckman SP; Hahn FM; Poulter CD; Ebetino FH; Rogers MJ
J Pharmacol Exp Ther; 2001 Feb; 296(2):235-42. PubMed ID: 11160603
[TBL] [Abstract][Full Text] [Related]
6. Antiresorptive dose-response relationships across three generations of bisphosphonates.
Sietsema WK; Ebetino FH; Salvagno AM; Bevan JA
Drugs Exp Clin Res; 1989; 15(9):389-96. PubMed ID: 2630251
[TBL] [Abstract][Full Text] [Related]
7. The intracellular target for the antiresorptive aminobisphosphonate drugs in Dictyostelium discoideum is the enzyme farnesyl diphosphate synthase.
Grove JE; Brown RJ; Watts DJ
J Bone Miner Res; 2000 May; 15(5):971-81. PubMed ID: 10804029
[TBL] [Abstract][Full Text] [Related]
8. The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase.
David P; Nguyen H; Barbier A; Baron R
J Bone Miner Res; 1996 Oct; 11(10):1498-507. PubMed ID: 8889850
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts.
Reinholz GG; Getz B; Pederson L; Sanders ES; Subramaniam M; Ingle JN; Spelsberg TC
Cancer Res; 2000 Nov; 60(21):6001-7. PubMed ID: 11085520
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonates: structure-activity relations from a clinical perspective.
Papapoulos SE
Medicina (B Aires); 1997; 57 Suppl 1():61-4. PubMed ID: 9567357
[TBL] [Abstract][Full Text] [Related]
11. Growth inhibition of macrophage-like and other cell types by liposome-encapsulated, calcium-bound, and free bisphosphonates in vitro.
Mönkkönen J; Taskinen M; Auriola SO; Urtti A
J Drug Target; 1994; 2(4):299-308. PubMed ID: 7858955
[TBL] [Abstract][Full Text] [Related]
12. Pyridinium-1-yl bisphosphonates are potent inhibitors of farnesyl diphosphate synthase and bone resorption.
Sanders JM; Song Y; Chan JM; Zhang Y; Jennings S; Kosztowski T; Odeh S; Flessner R; Schwerdtfeger C; Kotsikorou E; Meints GA; Gómez AO; González-Pacanowska D; Raker AM; Wang H; van Beek ER; Papapoulos SE; Morita CT; Oldfield E
J Med Chem; 2005 Apr; 48(8):2957-63. PubMed ID: 15828834
[TBL] [Abstract][Full Text] [Related]
13. [Preclinical toxicology of bisphosphonates].
Mondelo N; Peluffo VA; Parma MD; Cointry GR; Capozza RF; Ferretti JL; Piccinni E; Montuori E
Medicina (B Aires); 1997; 57 Suppl 1():93-100. PubMed ID: 9567361
[TBL] [Abstract][Full Text] [Related]
14. Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy.
Leu CT; Luegmayr E; Freedman LP; Rodan GA; Reszka AA
Bone; 2006 May; 38(5):628-36. PubMed ID: 16185944
[TBL] [Abstract][Full Text] [Related]
15. The effects of nitrogen-containing bisphosphonates on human epithelial (Caco-2) cells, an in vitro model for intestinal epithelium.
Twiss IM; Pas O; Ramp-Koopmanschap W; Den Hartigh J; Vermeij P
J Bone Miner Res; 1999 May; 14(5):784-91. PubMed ID: 10320527
[TBL] [Abstract][Full Text] [Related]
16. Structural requirements for bisphosphonate actions in vitro.
van Beek E; Hoekstra M; van de Ruit M; Löwik C; Papapoulos S
J Bone Miner Res; 1994 Dec; 9(12):1875-82. PubMed ID: 7872052
[TBL] [Abstract][Full Text] [Related]
17. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite.
Nancollas GH; Tang R; Phipps RJ; Henneman Z; Gulde S; Wu W; Mangood A; Russell RG; Ebetino FH
Bone; 2006 May; 38(5):617-27. PubMed ID: 16046206
[TBL] [Abstract][Full Text] [Related]
18. Lowering bone mineral affinity of bisphosphonates as a therapeutic strategy to optimize skeletal tumor growth inhibition in vivo.
Fournier PG; Daubiné F; Lundy MW; Rogers MJ; Ebetino FH; Clézardin P
Cancer Res; 2008 Nov; 68(21):8945-53. PubMed ID: 18974139
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of action of the bisphosphonates.
Fleisch H
Medicina (B Aires); 1997; 57 Suppl 1():65-75. PubMed ID: 9567358
[TBL] [Abstract][Full Text] [Related]
20. Bisphosphonates: mode of action and pharmacology.
Russell RG
Pediatrics; 2007 Mar; 119 Suppl 2():S150-62. PubMed ID: 17332236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
